Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2026)

Camp4 Therapeutics has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $105.5 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $105.5 million, up 68.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $360.9 million (up 122.19% YoY), and the FY2025 annual result was $117.8 million, up 50.44% from the prior year.
• Liabilities and Shareholders Equity came in at $105.5 million for Q1 2026 at Camp4 Therapeutics, down from $117.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $117.8 million in Q4 2025 to a low of $21.4 million in Q3 2024.
• The 4-year median for Liabilities and Shareholders Equity is $70.5 million (2024), against an average of $72.3 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 42.52% in 2024 and jumped 304.4% in 2025, its largest moves.
• Camp4 Therapeutics' Liabilities and Shareholders Equity stood at $54.9 million in 2023, then jumped by 42.52% to $78.3 million in 2024, then surged by 50.44% to $117.8 million in 2025, then retreated by 10.48% to $105.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $105.5 million (Q1 2026), $117.8 million (Q4 2025), and $86.4 million (Q3 2025), per Business Quant data.